Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413166 · ClinicalTrials.gov registry record · Phase 2
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
A Phase 2 study of Acute Promyelocytic Leukemia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT00413166 is a Phase 2 study of Acute Promyelocytic Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 78 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00413166, a Phase 2 study of Acute Promyelocytic Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if the combination of arsenic trioxide (ATO) with ATRA and possibly idarubicin is effective in treating patients with newly-diagnosed APL.
Conditions Studied
Interventions
- DRUG Gemtuzumab Ozogamicin
- DRUG Idarubicin
- DRUG All-Trans Retinoic Acid (ATRA)
- DRUG Arsenic Trioxide (ATO)
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2006-12 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413166
The ClinicalTrials.gov registry entry for NCT00413166 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Promyelocytic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Gemtuzumab Ozogamicin is the first listed.
NCT00413166 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00413166 about?
NCT00413166 is a clinical study titled "All-trans Retinoic Acid, and Arsenic +/- Idarubicin". The goal of this clinical research study is to learn if the combination of arsenic trioxide (ATO) with ATRA and possibly idarubicin is effective in treating patients with newly-diagnosed APL.
What is the current status of trial NCT00413166?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2006-12. Estimated completion is 2016-02.
What conditions does trial NCT00413166 study?
This clinical trial studies the following conditions: Acute Promyelocytic Leukemia.
What interventions are being tested in trial NCT00413166?
The interventions under investigation include: Gemtuzumab Ozogamicin (DRUG), Idarubicin (DRUG), All-Trans Retinoic Acid (ATRA) (DRUG), Arsenic Trioxide (ATO) (DRUG).
Who is sponsoring clinical trial NCT00413166?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00413166 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Promyelocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.